TY - JOUR
T1 - Burden or benefit? Effects of providing education about and the option to request additional genomic findings from diagnostic exome sequencing
T2 - A randomized controlled trial
AU - Rini, Christine
AU - Roche, Myra I.
AU - Lin, Feng Chang
AU - Foreman, Ann Katherine M.
AU - Khan, Cynthia M.
AU - Griesemer, Ida
AU - Waltz, Margaret
AU - Lee, Kristy
AU - O'Daniel, Julianne M.
AU - Evans, James P.
AU - Berg, Jonathan S.
AU - Henderson, Gail E.
N1 - Funding Information:
Research reported in this publication was supported by National Human Genome Research Institute (NHGRI), the National Cancer Institute (NCI) and the National Institute on Minority Health and Health Disparities (NIMHD) of the United States National Institutes of Health under award number U01HG006487 (PIs: James P. Evans, Jonathan S. Berg, Karen E. Weck, Kirk C. Wilhelmsen, and Gail E. Henderson). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or of the U.S. Government Accountability Office. We would like to thank Noel Brewer for his involvement in early plans for the study, Elizabeth Moore for her assistance with data collection, and the patients who participated in this research. Trial registration: clinicaltrials.gov NCT01969370.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/12
Y1 - 2021/12
N2 - Objective: Many people prefer to learn secondary or “additional” findings from genomic sequencing, including findings with limited medical actionability. Research has investigated preferences for and effects of learning such findings, but not psychosocial and behavioral effects of receiving education about them and the option to request them, which could be burdensome or beneficial (e.g., causing choice overload or satisfying strong preferences, respectively). Methods: 335 adults with suspected genetic disorders who had diagnostic exome sequencing in a research study and were randomized to receive either diagnostic findings only (DF; n = 171) or diagnostic findings plus education about additional genomic findings and the option to request them (DF + EAF; n = 164). Assessments occurred after enrollment (Time 1), after return of diagnostic results and—for DF + EAF—the education under investigation (Time 2), and three and six months later (Times 3, 4). Results: Time 2 test-related distress, test-related uncertainty, and generalized anxiety were lower in the DF + EAF group (ps = 0.025–0.043). There were no other differences. Conclusions: Findings show limited benefits and no harms of providing education about and the option to learn additional findings with limited medical actionability. Practice implications: Findings can inform recommendations for returning additional findings from genomic sequencing (e.g., to research participants or after commercial testing).
AB - Objective: Many people prefer to learn secondary or “additional” findings from genomic sequencing, including findings with limited medical actionability. Research has investigated preferences for and effects of learning such findings, but not psychosocial and behavioral effects of receiving education about them and the option to request them, which could be burdensome or beneficial (e.g., causing choice overload or satisfying strong preferences, respectively). Methods: 335 adults with suspected genetic disorders who had diagnostic exome sequencing in a research study and were randomized to receive either diagnostic findings only (DF; n = 171) or diagnostic findings plus education about additional genomic findings and the option to request them (DF + EAF; n = 164). Assessments occurred after enrollment (Time 1), after return of diagnostic results and—for DF + EAF—the education under investigation (Time 2), and three and six months later (Times 3, 4). Results: Time 2 test-related distress, test-related uncertainty, and generalized anxiety were lower in the DF + EAF group (ps = 0.025–0.043). There were no other differences. Conclusions: Findings show limited benefits and no harms of providing education about and the option to learn additional findings with limited medical actionability. Practice implications: Findings can inform recommendations for returning additional findings from genomic sequencing (e.g., to research participants or after commercial testing).
KW - Additional genomic findings
KW - Diagnostic sequencing
KW - Genomic sequencing
KW - Randomized controlled trial
KW - Test-related distress
UR - http://www.scopus.com/inward/record.url?scp=85106255604&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106255604&partnerID=8YFLogxK
U2 - 10.1016/j.pec.2021.04.026
DO - 10.1016/j.pec.2021.04.026
M3 - Article
C2 - 33966955
AN - SCOPUS:85106255604
SN - 0738-3991
VL - 104
SP - 2989
EP - 2998
JO - Patient Education and Counseling
JF - Patient Education and Counseling
IS - 12
ER -